Anzeige
Mehr »
Login
Sonntag, 09.08.2020 Börsentäglich über 12.000 News von 643 internationalen Medien
NEU! Unglaublich, aber wahr! Bis zu 1.000% mit dieser Gold-Kupfer-Aktie! Das ist Ihr nächstes Millionen-Los!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12HVG ISIN: US71715X1046 Ticker-Symbol: EFY 
Stuttgart
07.08.20
08:30 Uhr
0,012 Euro
-0,001
-4,00 %
1-Jahres-Chart
PHARMACYTE BIOTECH INC Chart 1 Jahr
5-Tage-Chart
PHARMACYTE BIOTECH INC 5-Tage-Chart

Aktuelle News zur PHARMACYTE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoPharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer6
29.07.PharmaCyte Biotech, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4057
29.07.PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests211PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box...
► Artikel lesen
PHARMACYTE Aktie jetzt für 0€ handeln
29.06.PharmaCyte Biotech's COVID-19 Test Offers "Pool Testing" Dr. Fauci and White House Coronavirus Task Force Now Considering9
18.05.PharmaCyte Conducts Final Audit of Mfg. Facility11
13.04.PharmaCyte Biotech to Offer COVID-19 Testing While Creating Revenue Stream for Pancreatic Cancer Program18
08.04.PharmaCyte Biotech enters into license agreement for COVID-19 diagnostic kits10
08.04.BRIEF-Pharmacyte Biotech Enters License Agreement For Covid-19 Diagnostic Kits2
08.04.PharmaCyte Biotech, Inc. - 8-K, Current Report1
26.03.PharmaCyte Biotech CEO Discusses Navigating Testing and IND Submission During COVID-19 Pandemic5
11.02.Will PharmaCyte Biotech's Cell-in-a-Box(R) Technology Be The Game Changer To Effectively Treating Pancreatic Cancer?359PCG Media covers the value that PharmaCyte's Cell-in-a-Box technology can bring to the pancreatic cancer market. Future indications expected to target diabetes and cannabinoid therapy.New York, New...
► Artikel lesen
06.02.PharmaCyte Biotech Exploits Potential Of Its Cell-in-a-Box(R) Technology; Targets Billion Dollar Cancer, Diabetes, and Medicinal Cannabinoid Markets321Soulstring Media Group covers how this emerging biotech can become a potential leader in treating pancreatic cancer and diabetes with its Cell-in-a-Box(R) technologyMiami Beach, Florida--(Newsfile Corp....
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2